Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients

Cites (264)

Items 201–256 of 256

1. Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial
   Ilaria Saltarella, Fortunato Morabito, Nicola Giuliani, Carolina Terragna, Paola Omedè, Antonio Pierangelo Palumbo, Sara Bringhen, Lorenzo De Paoli, Enrica Antonia Martino, Alessandra Larocca et al. · 2019 · Journal of Hematology & Oncology
2. Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma
   Joseph R Mikhael, Craig B. Reeder, Edward N. Libby, Luciano J. Costa, Peter Leif Bergsagel, Francis K. Buadi, Angela Mayo, Sravan K. Nagi Reddy, Katherine Gano, Amylou Constance Dueck et al. · 2015 · British Journal of Haematology
3. Endothelial Differentiation of Hematopoietic Stem and Progenitor Cells from Patients with Multiple Myeloma
   Roberto Ria, Cláudia Piccoli, Teresa Cirulli, Franca Falzetti, Giuseppe Mangialardi, Diego Guidolin, Antonio Tabilio, Nicola Di Renzo, Attilio Guarini, Doménico Ribatti et al. · 2008 · Clinical Cancer Research
4. Role of tumour angiogenesis in haematological malignancies
   Michael Medinger, Jakob Robert Passweg · 2014 · Swiss Medical Weekly
5. Low dose velcade, thalidomide and dexamethasone (LD-VTD): An effective regimen for relapsed and refractory multiple myeloma patients
   Stefania Ciolli, F. Leoni, Federica Gigli, Luigi Rigacci, Alberto Bosi · 2005 · Leukemia & lymphoma/Leukemia and lymphoma
6. Multiple Myeloma as a Model for the Role of Bone Marrow Niches in the Control of Angiogenesis
   Doménico Ribatti, Beatrice Nico, Angelo Vacca · 2014 · International review of cytology
7. Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets
   Simona Berardi, Antonella Caivano, Roberto Ria, Beatrice Nico, Rocco Savino, Rosa Terracciano, Giacoma De Tullio, Arianna Ferrucci, Annunziata De Luisi, Michele Moschetta et al. · 2011 · Oncogene
8. Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma
   Arianna Calcinotto, Maurilio Ponzoni, Roberto Ria, Matteo Grioni, Elena F. Cattaneo, Isabella Villa, Maria Teresa Sabrina Bertilaccio, Marta Chesi, Alessandro Rubinacci, Giovanni Tonon et al. · 2015 · OncoImmunology
9. Novel agents and new therapeutic approaches for treatment of multiple myeloma
   Roberto Ria · 2014 · World Journal of Methodology
10. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents
    María Teresa Cibeira, Marı́a Rozman, Marta Segarra, Ester Lozano, Laura Rosiñol, Maria Cinta Cid, Xavier Filella, Joan Bladé · 2008 · Cytokine
11. Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression
    Patrizia Mondello, Salvatore Cuzzocrea, Michele Navarra, Michael Mian · 2017 · Oncotarget
12. Sorafenib in patients with refractory or recurrent multiple myeloma
    Anna Yordanova, Dirk Hose, Kai Neben, Mathias Witzens‐Harig, Ines Gütgemann, Marc Steffen Raab, Thomas M. Moehler, Hartmut Goldschmidt, Ingo G.H. Schmidt‐Wolf · 2013 · Hematological Oncology
13. V. Molecular classification and risk stratification of myeloma
    Peter Leif Bergsagel, Marta Chesi · 2013 · Hematological Oncology
14. VEGF/VEGFR2 interaction down-regulates matrix metalloproteinase–9 via STAT1 activation and inhibits B chronic lymphocytic leukemia cell migration
    Estefanía Ugarte-Berzal, Javier Redondo-Muñóz, Pîlar Eroles, Mercedes Hernández del Cerro, Jose Antonio Garcia-Marco, María José Terol, Angeles Garcı́a-Pardo · 2009 · Blood
15. Thalidomide (5HPP-33) Suppresses Microtubule Dynamics and Depolymerizes the Microtubule Network by Binding at the Vinblastine Binding Site on Tubulin
    Aijaz Rashid, Annapurna Kuppa, Ambarish Kunwar, Dulal Panda · 2015 · Biochemistry
16. Generation of erythroid cells from polyploid giant cancer cells: re-thinking about tumor blood supply
    Zhigang Yang, Hong Yao, Fei Fei, Yu-Wei Li, J. Qu, Chunyuan Li, Shi-Wu Zhang · 2018 · Journal of Cancer Research and Clinical Oncology
17. Tubulin-polymerization inhibitors derived from thalidomide
    Shunsuke Inatsuki, Tomomi Noguchi, Hiroyuki Miyachi, Sawako Oda-Nakazato, Toyotaka Iguchi, Masahiro Kizaki, Yuichi Hashimoto, Hisayoshi Kobayashi · 2004 · Bioorganic & Medicinal Chemistry Letters
18. Functional and Biological Role of Endothelial Precursor Cells in Tumour Progression: A New Potential Therapeutic Target in Haematological Malignancies
    Antonia Reale, Assunta Melaccio, Aurelia Lamanuzzi, Ilaria Saltarella, Franco Dammacco, Angelo Vacca, Roberto Ria · 2015 · Stem Cells International
19. Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study
    Sjoerd Hovenga, Simon M. G. J. Daenen, Joost Th. M. de Wolf, Gustaaf Willem Van Imhoff, Hanneke C. Kluin‐Nelemans, Wim J. Sluiter, Edo Vellenga · 2004 · Annals of Hematology
20. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib
    Konstantinos Anargyrou, Evangelos Terpos, T. P. Vassilakopoulos, Anastasia G. Pouli, Sotirios P. Sachanas, Τατιάνα Τζένου, Stavroula Masouridis, Dimitrios Christoulas, Maria K. Angelopoulou, Evangelia Makrina Dimitriadou et al. · 2008 · Haematologica
21. Angiogenesis and Vasculogenesis in Multiple Myeloma: Role of Inflammatory Cells
    Angelo Vacca, Doménico Ribatti · 2011 · Recent results in cancer research/Recent Results in Cancer Research
22. Emerging antibodies for the treatment of multiple myeloma
    Flora Zagouri, Evangelos Terpos, Efstathios Kastritis, Meletios Athanasios Dimopoulos · 2016 · Expert Opinion on Emerging Drugs
23. Circulating vascular endothelial growth factor (VEGF) and its soluble receptors in patients with chronic lymphocytic leukemia.
    Joanna Góra‐Tybor, Jerzy Z. Błoński, Tadeusz Robak · 2005 · PubMed
24. Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies
    Shaji Kunnathu Kumar · 2017 · Hematology
25. Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms
    Umang Patel, Rajyalakshmi Luthra, Leonard Jeffrey Medeiros, Keyur Pravinchandra Patel · 2017 · Clinical Lymphoma Myeloma & Leukemia
26. A phase II trial of BAY 43‐9006 (sorafenib) ( NSC ‐724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434
    Gordan Srkalović, Mohamad A. Hussein, Antje Hoering, Jeffrey A. Zonder, Leslie L. Popplewell, Harsha Trivedi, Sandy Mazzoni, Rachel E. Sexton, Robert Zygmunt Orlowski, Bart Barlogie · 2014 · Cancer Medicine
27. Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma
    Shaji Kunnathu Kumar, Amrita Y. Krishnan, Betsy R LaPlant, Kristina M. Laumann, Vivek Roy, Todd M. Zimmerman, Morie Abraham Gertz, Francis K. Buadi, Keith E Stockerl-Goldstein, Ann Birgin et al. · 2015 · American Journal of Hematology
28. Inhibition of Endothelial Slit2/Robo1 Signaling by Thalidomide Restrains Angiogenesis by Blocking the PI3K/Akt Pathway
    Yinan Li, Sengwang Fu, Haiying Chen, Qian Feng, Yun–Jie Gao, Hanbing Xue, Zhi‐Zheng Ge, Jing‐Yuan Fang, Shudong Xiao · 2014 · Digestive Diseases and Sciences
29. Apoptosis Induction by Thalidomide: Critical for Limb Teratogenicity but Therapeutic Potential in Idiopathic Pulmonary Fibrosis?
    Jürgen Knobloch, David Jungck, Andrea Koch · 2011 · Current Molecular Pharmacology
30. Anti-Angiogenic Effect of Bortezomib in Patients with Multiple Myeloma
    Marianna Politou, Kikkeri N. Naresh, Evangelos Terpos, Danielle Crawley, Irvin A. Lampert, Jane F. Apperley, Amin Rahemtulla · 2005 · Acta Haematologica
31. Vitamin E and rutin synergistically inhibit expression of vascular endothelial growth factor through down-regulation of binding activity of activator protein-1 in human promyelocytic leukemia (HL-60) cells
    Cheng‐Hung Chuang, Chin‐Shiu Huang, Miao‐Lin Hu · 2009 · Chemico-Biological Interactions
32. Maintenance Therapy for Multiple Myeloma
    Philip L. McCarthy, Antonio Pierangelo Palumbo · 2014 · Hematology/Oncology Clinics of North America
33. Role of Endothelial Cells and Fibroblasts in Multiple Myeloma Angiogenic Switch
    Doménico Ribatti, Angelo Vacca · 2016 · Cancer treatment and research
34. Thalidomide‐induced angiopoietin 2, N otch1 and D ll4 downregulation under hypoxic condition in tissues with gastrointestinal vascular malformation and human umbilical vein endothelial cells
    Qian Feng, Hong Tan, Zhi Zheng Ge, Yun Jie Gao, Hui Min Chen, Shu Dong XIAO · 2013 · Journal of Digestive Diseases
35. The Analysis of the Relationship between Multiple Myeloma Cells and Their Microenvironment
    Artur J. Jurczyszyn, Anna Zebzda, Jacek Czepiel, Joanna Gdula‐Argasińska, William H. Perucki, Aleksander B. Skotnicki, Marcin Majka · 2015 · Journal of Cancer
36. Targeting the Bone Marrow Microenvironment
    Michele Moschetta, Yawara Kawano, Klaus Podar · 2016 · Cancer treatment and research
37. Epigenetics in Multiple Myeloma
    Siobhan V. Glavey, Salomon Manier, Antonio Sacco, Karma Ziad Salem, Yawara Kawano, Juliette Bouyssou, Irene M. Ghobrial, Aldo Maria Roccaro · 2016 · Cancer treatment and research
38. Lysophosphatidic acid receptor expression in chronic lymphocytic leukemia leads to cell survival mediated though vascular endothelial growth factor expression
    Sekar Ashok Kumar, Xiaojie Hu, Michelle Brown, Brenda Kuschak, Tiffany A. Hernandez, James B. Johnston, Spencer Bruce Gibson · 2009 · Leukemia & lymphoma/Leukemia and lymphoma
39. Effectiveness of targeted therapy as monotherapy or combined therapy in patients with relapsed or refractory multiple myeloma: A systematic review and meta-analysis
    Sylwia Łopuch, Paweł Kawalec, Natalia Wiśniewska · 2014 · Hematology
40. The Aplidin analogs PM01215 and PM02781 inhibit angiogenesis in vitro and in vivo
    Bojana Borjan, Normann Steiner, Silvia Karbon, Johann Kern, Andrés Francesch, Martin Hermann, Wolfgang Willenbacher, Eberhard Gunsilius, Gerold Untergasser · 2015 · BMC Cancer
41. Update on Multiple Myeloma
    Khalid Ahmed Al‐Anazi · 2019 · IntechOpen eBooks
42. A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005)
    Paul Gerard Guy Richardson, Craig C. Hofmeister, Noopur S Raje, David Samuel DiCapua Siegel, Sagar Lonial, Jacob P. Laubach, Yvonne Adeduni Efebera, David H. Vesole, Ajay K. Nooka, Jacalyn M. Rosenblatt et al. · 2015 · Blood
43. Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma
    Mohammed Junaid Hussain, Myra M Robinson, Issam S. Hamadeh, Justin R. Arnall, Manisha Bhutani, Shebli Atrash, Reed N. Friend, Mauricio Pineda‐Roman, James Thomas Symanowski, Saad Z. Usmani et al. · 2018 · British Journal of Haematology
44. The Role of Inflammatory Cells in Angiogenesis in Multiple Myeloma
    Doménico Ribatti, Angelo Vacca · 2014 · Advances in experimental medicine and biology
45. Enhanced growth suppression of Philadephia1 leukemia cells by targeting bcr3/abl2 and VEGF through antisense strategy
    X L Cong, Baozhong Li, Renchi Yang, Sizhou Feng, S J Chen, Zhongchao Han · 2005 · Leukemia
46. The Role of Angiogenesis in Hematologic Malignancies
    Roberto Stasi, Sergio Amadori · 2002 · Stem Cells and Development
47. Sorafenib for the treatment of multiple myeloma
    Massimo Gentile, Massimo Vincenzo Martino, Anna Grazia Recchia, Ernesto Vigna, Lucio Morabito, Fortunato Morabito · 2016 · Expert Opinion on Investigational Drugs
48. Multiple Myeloma: Is It Time for Biomarker-Driven Therapy?
    Manisha Bhutani, Ola Landgren, Saad Z. Usmani · 2015 · American Society of Clinical Oncology Educational Book
49. Changes in circulating endothelial progenitor cells predict responses of multiple myeloma patients to treatment with bortezomib and dexamethasone
    Lei Wang, Fei-Peng Du, Hua-Qiu Zhang, Wen-Zhi Zhang, Hong-Xiang Wang · 2015 · Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
50. Effects of a novel proteasome inhibitor BU-32 on multiple myeloma cells
    Sudipa Saha Roy, Nameer B. Kirma, Bindu Santhamma, RAJESHWAR RAO TEKMAL, Joseph K. Agyin · 2014 · Cancer Chemotherapy and Pharmacology
51. Phase II study of pegylated liposomal doxorubicin, low‐dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma
    Rachid Baz, Kenneth H. Shain, Mohamad A. Hussein, Ji‐Hyun Lee, Daniel M. Sullivan, Elizabeth Finley Oliver, Lisa Ann Nardelli, Lisa Nodzon, Xiuhua Zhao, Jose Leonel Ochoa-Bayona et al. · 2013 · American Journal of Hematology
52. The importance of antiangiogenic effect in multiple myeloma treatment
    Agnieszka Barchnicka, Małgorzata Olejniczak‐Nowakowska, Karolina Helena Krupa-Kotara, Sebastian Grosicki · 2018 · Advances in Clinical and Experimental Medicine
53. Phase 1 Trial of Sorafenib and Everolimus In Patients with Lymphoma or Multiple Myeloma.
    Shaji Kunnathu Kumar, Luis F. Porrata, Stephen Maxted Ansell, Joseph P Colgan, Betsy R LaPlant, Morie Abraham Gertz, David James Inwards, Patrick B. Johnston, Thomas M Haberman, Ivana N. Micallef et al. · 2010 · Blood
54. The MP0250-CP201 Mirror Study: A Phase 2 Study Update of MP0250 Plus Bortezomib and Dexamethasone in Relapse/Refractory Multiple Myeloma (RRMM) Patients Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs
    Norbert Grząśko, Stefan Tobias Knop, Hartmut Goldschmidt, Marc Steffen Raab, Jan Dürig, Sara Bringhen, Mattia D’Agostino, Barbara Gamberi, Elena Rivolti, Angelo Vacca et al. · 2019 · Blood
55. Angiogenesis and Antiangiogenesis in Multiple Myeloma
    Roberto Ria, Antonio Giovanni Solimando, Assunta Melaccio, Azzurra Sportelli, Angelo Vacca · 2019 · IntechOpen eBooks
56. The bone marrow microenvironment in multiple myeloma: Cellular and molecular basis of disease progression
    Roberto Ria, Antonia Reale, Giuseppe Mangialardi, Franco Dammacco, Doménico Ribatti, Angelo Vacca · 2010 · CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro)